Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2025, but sales fell by 5.6% year on year to $3.58 billion. The company expects the full year’s revenue to be around $13.75 billion, close to analysts’ estimates. Its non-GAAP profit of $0.62 per share was 11.4% above analysts’ consensus estimates.
Is now the time to buy VTRS? Find out in our full research report (it’s free).
Viatris (VTRS) Q2 CY2025 Highlights:
- Revenue: $3.58 billion vs analyst estimates of $3.44 billion (5.6% year-on-year decline, 4.2% beat)
- Adjusted EPS: $0.62 vs analyst estimates of $0.56 (11.4% beat)
- Adjusted EBITDA: $1.08 billion vs analyst estimates of $1.04 billion (30.1% margin, 3.7% beat)
- The company reconfirmed its revenue guidance for the full year of $13.75 billion at the midpoint
- Management reiterated its full-year Adjusted EPS guidance of $2.23 at the midpoint
- EBITDA guidance for the full year is $4.04 billion at the midpoint, in line with analyst expectations
- Operating Margin: 6.5%, up from -6.3% in the same quarter last year
- Market Capitalization: $11.8 billion
StockStory’s Take
Viatris’ second quarter was met with a significant positive market reaction, as investors responded to operational execution and margin improvement despite year-over-year revenue declines. Management credited underlying momentum to strength in Europe and Greater China, along with progress on its pipeline and tighter cost controls. CEO Scott Smith noted that “five of our six anticipated Phase III readouts have shown positive results,” emphasizing advancements in the company’s late-stage development programs. The quarter also reflected benefits from portfolio diversification and ongoing remediation at manufacturing sites.
Looking ahead, Viatris’ guidance rests on the continued ramp-up of late-stage pipeline assets, further cost containment, and steady contributions from its global generics and brands business. The company expects product launches in areas like ophthalmology, pain management, and women’s health to fuel mid-term growth, while strategic reviews focus on long-term efficiency. CFO Doretta Mistras stated, “We expect to be in the top half of the guidance range as a result of positive operational momentum and the year-to-date benefit from foreign exchange.” Management highlighted confidence in scaling the Eye Care division and launching novel products, but is monitoring regulatory, approval, and tariff risks.
Key Insights from Management’s Remarks
Management pointed to pipeline advancement, regional resilience, and cost-saving initiatives as the primary drivers of the quarter’s financial performance, with strategic business development and operational remediation also in focus.
- Pipeline progress drives optimism: Five of six anticipated Phase III readouts delivered positive results, including two ophthalmology programs and a fast-acting meloxicam candidate for acute pain, positioning the company for future branded launches.
- European and China market strength: Europe and Greater China outperformed expectations, with European brands like EpiPen and CREON contributing and China benefiting from diversified commercial channels and favorable purchasing patterns.
- Cost discipline and operational efficiencies: Operating expenses declined year-over-year due to ongoing cost-saving measures, particularly in selling, general, and administrative (SG&A) expenses, supporting margin recovery.
- Manufacturing remediation advances: Remediation at the Indore facility is nearing completion, and Viatris is seeking FDA engagement to facilitate reinspection, while the Nashik site received FDA approval for a key product, signaling operational progress.
- Enterprise-wide strategic review underway: The company is conducting a comprehensive review aimed at long-term efficiency and potential cost reductions, with management expecting to disclose detailed outcomes by the next quarterly call.
Drivers of Future Performance
Viatris’ forward guidance is anchored by expectations for new product launches, disciplined cost management, and stability in core markets, offset by potential regulatory and macroeconomic headwinds.
- Late-stage pipeline commercialization: Management anticipates several near-term product launches, including acute pain and ophthalmology assets, with particular focus on fast-acting meloxicam and MR-141 for presbyopia. These are expected to support revenue and margin growth into 2026 and beyond.
- Ongoing cost optimization: An enterprise-wide strategic review is underway to unlock further cost savings and operational efficiencies, with management indicating significant benefits are expected to emerge following its completion later this year.
- Tariff and regulatory risk monitoring: While management does not expect material financial impact from proposed U.S. tariffs in 2025, the company is closely watching policy developments and preparing contingency plans for potential effects on global supply chains and product sourcing.
Catalysts in Upcoming Quarters
As we look to the upcoming quarters, our analysts will be monitoring (1) the pace of late-stage pipeline progress and associated regulatory approvals, (2) the outcome and disclosed impact of the enterprise-wide strategic review, and (3) sustained commercial execution in key regions such as Europe and Greater China. The timing and success of new product launches, especially in the Eye Care division and acute pain, will also be key indicators of future momentum.
Viatris currently trades at $10.12, up from $8.74 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.
The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.